How Lab Owl Worked with FinaBio to Develop Vaccines for Low Income Countries Around the Globe
The Lab Owl™ and Fina Biosolutions Case Study
Fina Biosolutions Awarded $289,000 from NIAID to Develop Carrier Protein for Conjugate Vaccines
Rockville, Maryland’s Fina Biosolutions recently was awarded an SBIR grant to develop a genetically detoxified tetanus toxin as a carrier protein for conjugate vaccines. The NIAID funded grant is for $289,000 and…
Development of FinaBio’s CRM197, EcoCRM® and Ready-to-Conjugate(TM) carrier proteins
Development of FinaBio’s CRM197, EcoCRM® and Ready-to-ConjugateTM carrier proteins. Presented April 15, 2020 to the Canadian Glycomics Network About the Canadian Glycomics Network In 2015, the Canadian glycomics research community mobilized to…
Pneumosil®, from Serum Institute of India achieves WHO prequalification
Pneumosil®, from Serum Institute of India achieves WHO prequalification. At $2 per dose, Pneumosil® will be 30% less expensive than the current GAVI price for pneumococcal vaccines. It will also…
How PATH and FinaBio Make Vaccines Affordable
PATH (path.org), an organization promoting health in low income countries, has published an article on their smaller partners, including Fina Biosolutions. FinaBio has worked with PATH on conjugate vaccines for…
Polyvalent meningococcal conjugate vaccine enters late-stage clinical study
A meningococcal conjugate vaccine using chemistry developed at Fina Biosolutions has entered a pivotal phase III trial. FinaBio patents for CPIP conjugation were exclusively licensed to the Serum Institute of…
FinaBio Signs Development Agreement with Kunming
Fina Biosolutions LLC of Rockville, MD has signed a development agreement for two conjugate vaccines with the Chinese Institute of Medical Biology (Kunming), part of the Chinese Academy of Medicine.…
Fina Biosolutions’ Dr. Andrew Lees joins Rich Bendis on BioTalk to discuss their technology, how they partner with Biotech companies and their future
BioTalk summary here. Listen now on Google Play bit.ly/2CzdnA9, iTunes, apple.co/2Arsfze, TuneIn bit.ly/2M60Wmx.
Fina Biosolutions’ Licensee Successfully Completes a Phase 3 Study and Enters World Health Organization (WHO) Registration for Pneumosil®
For Immediate Release: Fina Biosolutions’ Licensee Successfully Completes a Phase 3 Study and Enters World Health Organization (WHO) Registration for Pneumosil® Serum Institute of India completes a Phase 3 clinical trial…
Maryland Tech Council’s Interview with Dr. Andrew Lees
Last month, the Maryland Tech Council stopped by Fina Biosolutions, where they met with Founder, CEO and Chief Scientific Officer, Dr. Andrew Lees. Dr. Lees was a gracious host, giving…